Cargando…

High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy

Carbohydrate antigen 19-9 (CA19-9) is one of the most widely used tumor markers in gastrointestinal cancer. However, serum CA19-9 is not a recommended routine measurement in colon cancer. In this study, we evaluated the value of the preoperative serum CA19-9 level for the prediction of postoperative...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wenhao, Yang, Fan, Peng, Jianhong, Wang, Fulong, Lin, Yuzhu, Jiang, Wu, Yang, Xia, Li, Liren, Lu, Zhenhai, Wan, Desen, Pan, Zhizhong, Fan, Wenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636281/
https://www.ncbi.nlm.nih.gov/pubmed/31333798
http://dx.doi.org/10.7150/jca.31375
_version_ 1783436035511812096
author Zhou, Wenhao
Yang, Fan
Peng, Jianhong
Wang, Fulong
Lin, Yuzhu
Jiang, Wu
Yang, Xia
Li, Liren
Lu, Zhenhai
Wan, Desen
Pan, Zhizhong
Fan, Wenhua
author_facet Zhou, Wenhao
Yang, Fan
Peng, Jianhong
Wang, Fulong
Lin, Yuzhu
Jiang, Wu
Yang, Xia
Li, Liren
Lu, Zhenhai
Wan, Desen
Pan, Zhizhong
Fan, Wenhua
author_sort Zhou, Wenhao
collection PubMed
description Carbohydrate antigen 19-9 (CA19-9) is one of the most widely used tumor markers in gastrointestinal cancer. However, serum CA19-9 is not a recommended routine measurement in colon cancer. In this study, we evaluated the value of the preoperative serum CA19-9 level for the prediction of postoperative prognosis in stage III colon cancer. The medical records of 367 consecutive patients with stage III colon cancer who underwent curative resection followed by adjuvant chemotherapy with oxaliplatin and capecitabine between December 2007 and April 2015 were retrospectively reviewed. We determined the optimal cutoff value of CA19-9 for 3-year recurrence using the receiver operating characteristic (ROC) method. Differences in disease-free survival (DFS) and overall survival (OS) rates stratified by CA19-9 level were compared by using Kaplan-Meier and log-rank tests. A Cox proportional hazards model was used to identify prognostic variables for DFS and OS. The statistically determined best cutoff value for CA19-9 was 24 U/ml. High CA19-9 levels (> 24 U/ml) were significantly associated with poorly differentiated tumors, abnormal carcinoembryonic antigen (CEA) levels, and a high cumulative incidence of lung metastasis. Additionally, compared with low CA19-9 levels, high preoperative CA19-9 levels were associated with inferior 3-year DFS and OS rates, especially for high-risk patients (T4Nany or TanyN2). Multivariate analyses revealed that CA19-9 was an independent factor associated with both DFS (hazard ratio [HR], 2.248; 95% confidence interval [CI], 1.393-3.628; P = 0.001) and OS (HR: 2.081; 95% CI: 1.137-3.808; P = 0.017). The results of this study showed that high levels of preoperative serum CA19-9 indicated a worse prognostic outcome for stage III colon cancer patients. An early follow-up protocol to assess lung metastasis and a full course of adjuvant chemotherapy should be used for these patients.
format Online
Article
Text
id pubmed-6636281
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-66362812019-07-22 High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy Zhou, Wenhao Yang, Fan Peng, Jianhong Wang, Fulong Lin, Yuzhu Jiang, Wu Yang, Xia Li, Liren Lu, Zhenhai Wan, Desen Pan, Zhizhong Fan, Wenhua J Cancer Research Paper Carbohydrate antigen 19-9 (CA19-9) is one of the most widely used tumor markers in gastrointestinal cancer. However, serum CA19-9 is not a recommended routine measurement in colon cancer. In this study, we evaluated the value of the preoperative serum CA19-9 level for the prediction of postoperative prognosis in stage III colon cancer. The medical records of 367 consecutive patients with stage III colon cancer who underwent curative resection followed by adjuvant chemotherapy with oxaliplatin and capecitabine between December 2007 and April 2015 were retrospectively reviewed. We determined the optimal cutoff value of CA19-9 for 3-year recurrence using the receiver operating characteristic (ROC) method. Differences in disease-free survival (DFS) and overall survival (OS) rates stratified by CA19-9 level were compared by using Kaplan-Meier and log-rank tests. A Cox proportional hazards model was used to identify prognostic variables for DFS and OS. The statistically determined best cutoff value for CA19-9 was 24 U/ml. High CA19-9 levels (> 24 U/ml) were significantly associated with poorly differentiated tumors, abnormal carcinoembryonic antigen (CEA) levels, and a high cumulative incidence of lung metastasis. Additionally, compared with low CA19-9 levels, high preoperative CA19-9 levels were associated with inferior 3-year DFS and OS rates, especially for high-risk patients (T4Nany or TanyN2). Multivariate analyses revealed that CA19-9 was an independent factor associated with both DFS (hazard ratio [HR], 2.248; 95% confidence interval [CI], 1.393-3.628; P = 0.001) and OS (HR: 2.081; 95% CI: 1.137-3.808; P = 0.017). The results of this study showed that high levels of preoperative serum CA19-9 indicated a worse prognostic outcome for stage III colon cancer patients. An early follow-up protocol to assess lung metastasis and a full course of adjuvant chemotherapy should be used for these patients. Ivyspring International Publisher 2019-06-09 /pmc/articles/PMC6636281/ /pubmed/31333798 http://dx.doi.org/10.7150/jca.31375 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Zhou, Wenhao
Yang, Fan
Peng, Jianhong
Wang, Fulong
Lin, Yuzhu
Jiang, Wu
Yang, Xia
Li, Liren
Lu, Zhenhai
Wan, Desen
Pan, Zhizhong
Fan, Wenhua
High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy
title High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy
title_full High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy
title_fullStr High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy
title_full_unstemmed High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy
title_short High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy
title_sort high pretreatment serum ca19-9 level predicts a poor prognosis for patients with stage iii colon cancer after curative resection and adjuvant chemotherapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636281/
https://www.ncbi.nlm.nih.gov/pubmed/31333798
http://dx.doi.org/10.7150/jca.31375
work_keys_str_mv AT zhouwenhao highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT yangfan highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT pengjianhong highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT wangfulong highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT linyuzhu highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT jiangwu highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT yangxia highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT liliren highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT luzhenhai highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT wandesen highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT panzhizhong highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy
AT fanwenhua highpretreatmentserumca199levelpredictsapoorprognosisforpatientswithstageiiicoloncanceraftercurativeresectionandadjuvantchemotherapy